ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
https://investors.oricpharma.com/news-releases/news-release-details/oric-pharmaceuticals-announces-clinical-supply-agreement
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
https://investors.oricpharma.com/news-releases/news-release-details/oricr-pharmaceuticals-provides-early-phase-1b-combination-data
ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line…
Phase 1b combination trial of ORIC-114 and subcutaneous amivantamab in patients with 1L NSCLC with EGFR exon 20 insertion mutations expected to initiate in Q1 2025, with initial data in mid-2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 13, 2025 (GLOBE…
January 13, 2025 3K 31
